LetterLetter
Open Access

Antibiotics and probiotics differentially shape immunotherapy outcomes in non-small cell lung cancer

Shuling Ma, Zijun Zhai, Rui Ding, Shijie Shang, Xinyi Liang, Shan Yin, Haofeng Lin, Guomeng Sha, Ran Zhang, Jinming Yu, Qian Song and Dawei Chen
Cancer Biology & Medicine May 2026, 20250844; DOI: https://doi.org/10.20892/j.issn.2095-3941.2025.0844

References

  1. 1.↵
    2. Mountzios G,
    3. Remon J,
    4. Hendriks LEL,
    5. García-Campelo R,
    6. Rolfo C,
    7. Van Schil P, et al.
    Immune-checkpoint inhibition for resectable non-small-cell lung cancer — opportunities and challenges. Nat Rev Clin Oncol. 2023; 20: 664–77.
    OpenUrlCrossRefPubMed
  2. 2.↵
    2. Song Q,
    3. Li X,
    4. Li Q,
    5. Shang S,
    6. Ma S,
    7. Zhai Z, et al.
    Bifidobacterium animalis suppresses non-small cell lung cancer progression and modulates tumor immunity through indole-3-acetic acid. Cell Rep. 2025; 44: 116132.
  3. 3.
    2. Derosa L,
    3. Hellmann MD,
    4. Spaziano M,
    5. Halpenny D,
    6. Fidelle M,
    7. Rizvi H, et al.
    Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer. Ann Oncol. 2018; 29: 1437–44.
    OpenUrlCrossRefPubMed
  4. 4.
    2. Huemer F,
    3. Rinnerthaler G,
    4. Westphal T,
    5. Hackl H,
    6. Hutarew G,
    7. Gampenrieder SP, et al.
    Impact of antibiotic treatment on immune-checkpoint blockade efficacy in advanced non-squamous non-small cell lung cancer. Oncotarget. 2018; 9: 16512.
  5. 5.
    2. Zhao S,
    3. Gao G,
    4. Li W,
    5. Li X,
    6. Zhao C,
    7. Jiang T, et al.
    Antibiotics are associated with attenuated efficacy of anti-PD-1/PD-L1 therapies in Chinese patients with advanced non-small cell lung cancer. Lung Cancer. 2019; 130: 10–7.
    OpenUrlCrossRefPubMed
  6. 6.
    2. Barrón F,
    3. Arrieta OG,
    4. Cardona A,
    5. Ruiz-Patiño A,
    6. Barrón Z,
    7. Rojas L.
    Relevance of antibiotic use on clinical activity of immune checkpoint inhibitors in Hispanic patients with advanced NSCLC (CLICAP-ABs). Technol Cancer Res Treat. 2019; 4.
  7. 7.
    2. Bagley SJ,
    3. Dhopeshwarkar N,
    4. Narayan V,
    5. Meropol NJ,
    6. Mamtani R,
    7. Boursi B.
    Impact of antibiotics (ABX) on overall survival (OS) in patients (pts) with advanced non-small-cell lung cancer (aNSCLC) and melanoma (aMel) treated with first-line immune checkpoint inhibition (ICI). J Clin Oncol. 2019; 37: e20643.
  8. 8.
    2. Hakozaki T,
    3. Okuma Y,
    4. Omori M,
    5. Hosomi Y.
    Impact of prior antibiotic use on the efficacy of nivolumab for non-small cell lung cancer. Oncol Lett. 2019; 17: 2946–52.
    OpenUrlCrossRefPubMed
  9. 9.
    2. Kim H,
    3. Lee JE,
    4. Hong SH,
    5. Lee MA,
    6. Kang JH,
    7. Kim IH.
    The effect of antibiotics on the clinical outcomes of patients with solid cancers undergoing immune checkpoint inhibitor treatment: a retrospective study. BMC Cancer. 2019; 19: 1100.
    OpenUrlPubMed
  10. 10.
    2. Pinato DJ,
    3. Howlett S,
    4. Ottaviani D,
    5. Urus H,
    6. Patel A,
    7. Mineo T, et al.
    Association of prior antibiotic treatment with survival and response to immune checkpoint inhibitor therapy in patients with cancer. JAMA Oncol. 2019; 5: 1774–8.
    OpenUrlPubMed
  11. 11.
    2. Ouaknine Krief J,
    3. Helly de Tauriers P,
    4. Dumenil C,
    5. Neveux N,
    6. Dumoulin J,
    7. Giraud V, et al.
    Role of antibiotic use, plasma citrulline and blood microbiome in advanced non-small cell lung cancer patients treated with nivolumab. J Immunother Cancer. 2019; 7: 176.
    OpenUrlAbstract/FREE Full Text
  12. 12.
    2. Mielgo Rubio X,
    3. Aguado C,
    4. Sereno M,
    5. Chara L,
    6. Cabezón L,
    7. Velastegui A, et al.
    Early antibiotic use affects the efficacy of first line immunotherapy in lung cancer patients but route of administration seems to be decisive. J Thorac Oncol. 2019; 14: S445.
    OpenUrl
  13. 13.
    2. Schett A,
    3. Rothschild SI,
    4. Curioni-Fontecedro A,
    5. Krähenbühl S,
    6. Früh M,
    7. Schmid S, et al.
    Predictive impact of antibiotics in patients with advanced non small-cell lung cancer receiving immune checkpoint inhibitors: antibiotics immune checkpoint inhibitors in advanced NSCLC. Cancer Chemother Pharmacol. 2020; 85: 121–31.
    OpenUrlPubMed
  14. 14.
    2. Chalabi M,
    3. Cardona A,
    4. Nagarkar DR,
    5. Dhawahir Scala A,
    6. Gandara DR,
    7. Rittmeyer A, et al.
    Efficacy of chemotherapy and atezolizumab in patients with non-small-cell lung cancer receiving antibiotics and proton pump inhibitors: pooled post hoc analyses of the OAK and POPLAR trials. Ann Oncol. 2020; 31: 525–31.
    OpenUrlCrossRefPubMed
  15. 15.
    2. Cortellini A,
    3. Di Maio M,
    4. Nigro O,
    5. Leonetti A,
    6. Cortinovis DL,
    7. Aerts JG, et al.
    Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy. J Immunother Cancer. 2021; 9: e002421.
  16. 16.
    2. Hamada K,
    3. Yoshimura K,
    4. Hirasawa Y,
    5. Hosonuma M,
    6. Murayama M,
    7. Narikawa Y, et al.
    Antibiotic usage reduced overall survival by over 70% in non-small cell lung cancer patients on anti-PD-1 immunotherapy. Anticancer Res. 2021; 41: 4985–93.
    OpenUrlAbstract/FREE Full Text
  17. 17.
    2. Verschueren MV,
    3. van der Welle CMC,
    4. Tonn M,
    5. Schramel FMNH,
    6. Peters BJM,
    7. van de Garde EMW.
    The association between gut microbiome affecting concomitant medication and the effectiveness of immunotherapy in patients with stage IV NSCLC. Sci Rep. 2021; 11: 23331.
  18. 18.
    2. Ren ZG,
    3. Gao Y,
    4. Wei C,
    5. Li X,
    6. Liu S,
    7. Zhang J, et al.
    968P Association between use of antibiotics (ATB) and clinical outcomes with tislelizumab (tisle) monotherapy. Ann Oncol. 2021; 32: S835.
    OpenUrlCrossRef
  19. 19.
    2. Balado AC,
    3. Lores MT,
    4. Sánchez RÁ,
    5. Ferrán BB,
    6. Montero EL,
    7. Torre AM, et al.
    4CPS-301 Association of antibiotics and proton pump inhibitors on clinical activity of firstline pembrolizumab for non-small cell lung cancer: 2 years of real world data. Eur J Hosp Pharm. 2021; 28: A65.
    OpenUrlAbstract/FREE Full Text
  20. 20.
    2. Castello A,
    3. Rossi S,
    4. Toschi L,
    5. Lopci E.
    Impact of antibiotic therapy and metabolic parameters in non-small cell lung cancer patients receiving checkpoint inhibitors. J Clin Med. 2021; 10: 1251.
    OpenUrlPubMed
  21. 21.
    2. Geum MJ,
    3. Kim C,
    4. Kang JE,
    5. Choi JH,
    6. Kim JS,
    7. Son ES, et al.
    Broad-spectrum antibiotic regimen affects survival in patients receiving nivolumab for non-small cell lung cancer. Pharmaceuticals (Basel). 2021; 14: 445.
    OpenUrlPubMed
  22. 22.
    2. Ochi N,
    3. Ichihara E,
    4. Takigawa N,
    5. Harada D,
    6. Inoue K,
    7. Shibayama T, et al.
    The effects of antibiotics on the efficacy of immune checkpoint inhibitors in patients with non–small-cell lung cancer differ based on PD-L1 expression. Eur J Cancer. 2021; 149: 73–81.
    OpenUrlPubMed
  23. 23.
    2. Lu PH,
    3. Tsai TC,
    4. Chang JWC,
    5. Deng ST,
    6. Cheng CY.
    Association of prior fluoroquinolone treatment with survival outcomes of immune checkpoint inhibitors in Asia. J Clin Pharm Ther. 2021; 46: 408–14.
    OpenUrlPubMed
  24. 24.
    2. Nyein AF,
    3. Bari S,
    4. Hogue S,
    5. Zhao Y,
    6. Maller B,
    7. Sha S, et al.
    Effect of prior antibiotic or chemotherapy treatment on immunotherapy response in non-small cell lung cancer. BMC Cancer. 2022; 22: 101.
    OpenUrlPubMed
  25. 25.
    2. Qiu H,
    3. Ma QG,
    4. Chen XT,
    5. Wen X,
    6. Zhang N,
    7. Liu WM, et al.
    Different classes of antibiotics exhibit disparate negative impacts on the therapeutic efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer patients. Am J Cancer Res. 2022; 12: 3175–84.
    OpenUrlPubMed
  26. 26.
    2. Joshi I,
    3. Peravali M,
    4. Geng X,
    5. Rao S,
    6. Chen KY,
    7. Veytsman I, et al.
    Impact of baseline clinical biomarkers on treatment outcomes in patients with advanced NSCLC receiving first-line pembrolizumab-based therapy. Clin Lung Cancer. 2022; 23: 438–45.
    OpenUrlPubMed
  27. 27.
    2. Stokes WA,
    3. Behera M,
    4. Jiang R,
    5. Gutman D,
    6. Giuste F,
    7. Burns A, et al.
    Effect of antibiotic therapy on immunotherapy outcomes for non-small cell lung cancer: analysis from the Veterans Health Administration Database. J Clin Oncol. 2021; 39: 9017.
    OpenUrl
  28. 28.
    2. Alkan Şen G,
    3. Şentürk Öztaş N,
    4. Değerli E,
    5. Can G,
    6. Turna H,
    7. Özgüroğlu M.
    Effect of antibiotic treatment on immune checkpoint inhibitors efficacy in patients with advanced non-small cell lung cancer. Lung Cancer. 2023; 184: 107347.
  29. 29.
    2. Deng F,
    3. Du X,
    4. Zhang P,
    5. Xu J,
    6. Li Y,
    7. Yang Z.
    Impact of antibiotic on efficacy and adverse reactions of chemoimmunotherapy in non-small cell lung cancer patients: a retrospective cohort study. Thorac Cancer. 2024; 15: 2560–9.
    OpenUrlPubMed
  30. 30.
    2. Tamura K,
    3. Okuma Y,
    4. Nomura S,
    5. Fukuda A,
    6. Masuda K,
    7. Matsumoto Y, et al.
    Efficacy and safety of chemoimmunotherapy in advanced non-small cell lung cancer patients with antibiotics-induced dysbiosis: a propensity-matched real-world analysis. J Cancer Res Clin Oncol. 2024; 150: 216.
    OpenUrlPubMed
  31. 31.
    2. Luo WC,
    3. Mei SQ,
    4. Huang ZJ,
    5. Chen ZH,
    6. Zhang YC,
    7. Yang MY, et al.
    Correlation of distribution characteristics and dynamic changes of gut microbiota with the efficacy of immunotherapy in EGFR-mutated non-small cell lung cancer. J Transl Med. 2024; 22: 326.
    OpenUrlPubMed
  32. 32.
    2. Xie Y.
    A study on the impact of antibiotics on the efficacy and prognosis of advanced lung cancer patients undergoing immune checkpoint inhibitor therapy. Eur Respir J. 2024; 64: PA5129.
  33. 33.
    2. Rousseau A,
    3. Simon-Tillaux N,
    4. Michiels S,
    5. Derosa L,
    6. Laparra A,
    7. Planchard D, et al.
    Concomitant comedications and survival with first-line pembrolizumab in advanced non–small-cell lung cancer. JAMA Netw Open. 2025; 8: e2529225.
  34. 34.
    2. Ochi N,
    3. Ichihara E,
    4. Yokoyama T,
    5. Inoue K,
    6. Tamura T,
    7. Watanabe H, et al.
    Impact of antibiotic use on survival in patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitor and chemotherapy. Int J Clin Oncol. 2025; 30: 2277–86.
    OpenUrlPubMed
  35. 35.
    2. Hu T,
    3. Li L,
    4. Cui J,
    5. Song X,
    6. Zhu H,
    7. Hou ZW, et al.
    Effects of antibiotics on immunotherapy in patients with metastatic nonsmall cell lung cancer. Eur J Cancer Prev. 2025; 34: 363–71.
    OpenUrlPubMed
  36. 36.↵
    2. Eng L,
    3. Sutradhar R,
    4. Niu Y,
    5. Liu N,
    6. Liu Y,
    7. Kaliwal Y, et al.
    Impact of antibiotic exposure before immune checkpoint inhibitor treatment on overall survival in older adults with cancer: a population-based study. J Clin Oncol. 2023; 41: 3122–34.
    OpenUrlPubMed
  37. 37.↵
    2. Metselaar-Albers M,
    3. Meijerman I,
    4. Engels F,
    5. Haanen J,
    6. Beijnen J,
    7. Lalmohamed A.
    No detrimental association between antibiotic use and immune checkpoint inhibitor therapy: an observational cohort study comparing patients with ICI-treated and TKI-treated melanoma and NSCLC. J Immunother Cancer. 2024; 12: e008269.
  38. 38.↵
    2. Nakatsukasa H,
    3. Takahashi M,
    4. Shibano M,
    5. Ishigami Y,
    6. Kawaguchi T,
    7. Nakamura Y, et al.
    Clinical impact of concomitant BIO-three use in advanced or recurrent non-small cell lung cancer treated with immune-checkpoint inhibitor. Int J Clin Oncol. 2024; 29: 1840–9.
    OpenUrlPubMed
  39. 39.↵
    2. Wang X,
    3. Fang Y,
    4. Liang W,
    5. Wong CC,
    6. Qin H,
    7. Gao Y, et al.
    Fusobacterium nucleatum facilitates anti-PD-1 therapy in microsatellite stable colorectal cancer. Cancer Cell. 2024; 42: 1729–46.e8.
    OpenUrlCrossRefPubMed
  40. 40.↵
    2. Lurienne L,
    3. Cervesi J,
    4. Duhalde L,
    5. de Gunzburg J,
    6. Andremont A,
    7. Zalcman G, et al.
    NSCLC immunotherapy efficacy and antibiotic use: a systematic review and meta-analysis. J Thorac Oncol. 2020; 15: 1147–59.
    OpenUrlCrossRefPubMed
  41. 41.↵
    2. Elkrief A,
    3. Méndez-Salazar EO,
    4. Maillou J,
    5. Vanderbilt CM,
    6. Gogia P,
    7. Desilets A, et al.
    Antibiotics are associated with worse outcomes in lung cancer patients treated with chemotherapy and immunotherapy. NPJ Precis Oncol. 2024; 8: 143.
    OpenUrlPubMed
Back to top

In this issue

Print
Download PDF
Email Article
Citation Tools

Jump to section